Madrigal Pharmaceuticals presents new data from Phase 3 MAESTRO-NASH trial

Madrigal Pharmaceuticals announced new data from the Phase 3 MAESTRO-NASH trial demonstrating broad treatment effects of resmetirom on noninvasive tests that may be used to monitor NASH with liver fibrosis. The noninvasive testing data and multiple additional abstracts from the MAESTRO program are being presented at the American Association for the Study of Liver Diseases, AASLD, Liver Meeting, taking place in Boston from November 10-14, 2023. In MAESTRO-NASH, resmetirom treatment helped patients with NASH with significant fibrosis as diagnosed on liver biopsy achieve improvements in liver enzymes, magnetic resonance imaging-proton density fat fraction, magnetic resonance elastography, FibroScan Vibration Controlled Transient Elastography, FibroScan Controlled Attenuation Parameter, and the Enhanced Liver Fibrosis test. Resmetirom also reduced levels of LDL cholesterol and other lipids that are associated with heart disease. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, “It is encouraging to see such a broad and consistent treatment response with resmetirom across multiple noninvasive tests, from simple blood-based tests that are widely used in clinical practice today to advanced imaging tests that will play a larger role in future care pathways for NASH. If resmetirom receives accelerated approval, clinicians will have many opportunities to highlight treatment response for their patients over time; even something as readily measurable as an improvement in ALT or LDL can be highly motivating for patients and support treatment adherence.”